BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1469 related articles for article (PubMed ID: 19698011)

  • 1. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
    Abe M; Okada K; Maruyama T; Matsumoto K
    Pharmacotherapy; 2009 Sep; 29(9):1061-72. PubMed ID: 19698011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria.
    Kohlmann O; Roca-Cusachs A; Laurent S; Schmieder RE; Wenzel RR; Fogari R
    Adv Ther; 2009 Mar; 26(3):313-24. PubMed ID: 19330493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
    Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
    Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study.
    Koren-Michowitz M; Dishy V; Zaidenstein R; Yona O; Berman S; Weissgarten J; Golik A
    Am J Hypertens; 2005 Mar; 18(3):358-63. PubMed ID: 15797654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
    Ellis D; Vats A; Moritz ML; Reitz S; Grosso MJ; Janosky JE
    J Pediatr; 2003 Jul; 143(1):89-97. PubMed ID: 12915830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan with hydrochlorothiazide in the treatment of hypertension.
    Schoenberger JA;
    J Hypertens Suppl; 1995 Jul; 13(1):S43-7. PubMed ID: 18800455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
    Minutolo R; Gabbai FB; Borrelli S; Scigliano R; Trucillo P; Baldanza D; Laurino S; Mascia S; Conte G; De Nicola L
    Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease.
    Abe M; Okada K; Maruyama T; Matsumoto K
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):525-32. PubMed ID: 19640361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension.
    Saruta T; Ogihara T; Matsuoka H; Suzuki H; Toki M; Hirayama Y; Nonaka K; Takahashi K
    Hypertens Res; 2007 Aug; 30(8):729-39. PubMed ID: 17917321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).
    Joshi SR; Yeolekar ME; Tripathi KK; Giri J; Maity AK; Chopda M; Gujarathi S; Maroli S; Maity A;
    J Assoc Physicians India; 2004 Mar; 52():189-95. PubMed ID: 15636307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
    de la Sierra A; Gil-Extremera B; Calvo C; Campo C; García-Puig J; Márquez E; Oliván J; Roca Cusachs A; Sanz de Castro S; Pontes C; Delgadillo J
    J Hum Hypertens; 2004 Mar; 18(3):215-22. PubMed ID: 14973517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
    Kim SH; Chung WY; Zo JH; Kim MA; Chang HJ; Cho YS; Youn TJ; Chae IH; Choi DJ; Gwak JJ; Lee HY; Park JS; Kang HJ; Kim YJ; Kim HS
    Clin Ther; 2009 May; 31(5):988-98. PubMed ID: 19539099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
    Roca-Cusachs A; Schmieder RE; Triposkiadis F; Wenzel RR; Laurent S; Kohlmann O; Fogari R;
    J Hypertens; 2008 Apr; 26(4):813-8. PubMed ID: 18327093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
    Lin SL; Chen YM; Chiang WC; Wu KD; Tsai TJ
    Am J Kidney Dis; 2008 Sep; 52(3):464-74. PubMed ID: 18617301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies.
    Naidoo DP; Sareli P; Marin F; Aroca-Martinez G; Maritz FJ; Jardim PC; Guerrero AA; Thompson CA; Bero T; Drazka J; Kosmalova V; Dumortier T; Smith RD
    Adv Ther; 1999; 16(5):187-99. PubMed ID: 10915394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
    Ellis D; Moritz ML; Vats A; Janosky JE
    Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide.
    Abe M; Okada K; Matsumoto K
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1285-303. PubMed ID: 19761411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.